Trial: 202006122

BR-076: A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer

Phase

II (Cancer Control)

Principal Investigator

Ademuyiwa, Foluso

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov